Jazz Pharmaceuticals valuation
Valuation
The P/E ratio is 71.5. The average price target of 22 analysts is $297.59.
Data as of November 15, 2026
Jazz Pharmaceuticals compared with similar companies
Jazz Pharmaceuticals's P/E (trailing 12 months): 71.5, +87% against the median of a group of 7 similar companies (38.3).
| Metric | Jazz Pharmaceuticals | Median | 25th–75th percentile | Band |
|---|---|---|---|---|
| P/E (trailing 12 months) | 71.5 | 38.3 | 19.1 – 69.1 | High |
| Forward P/E | 9.04 | 15.5 | 9.15 – 25.0 | Low |
| EV/EBITDA | 9.10 | 17.0 | 13.4 – 27.9 | Low |
| Price/book | 3.69 | 7.54 | 4.09 – 14.6 | Low |
| Price/sales | 3.29 | 7.23 | 4.95 – 9.17 | Low |
| Gross margin | 91.1% | 77.3% | 71.2% – 91.5% | Middle |
| Operating margin | 27.4% | 19.5% | -5.3% – 29.2% | Middle |
| Net margin | 4.4% | 4.4% | -5.7% – 30.2% | Middle |
| ROE | 5.1% | 8.3% | -4.2% – 88.3% | Middle |
| Debt/equity | 1.35 | 0.30 | 0.06 – 0.75 | High |
Group: the stock and up to 10 companies in the same industry (with fewer than 5, related industries too), same region first, with a similar size. Band: low = the lowest quarter of values in the group, middle = 25th to 75th percentile, high = the highest quarter. Negative multiples and multiples above 500 are excluded; a comparison needs at least 5 values. The group is recalculated nightly.
TickerLandia analysisHow it is calculated
Companies in the group: same industry, similar size
Jazz Pharmaceuticals: valuation over time
Jazz Pharmaceuticals P/E and dividend yield at each fiscal year end, 2016 to 2025.
| Fiscal year | Price at year end | Earnings per share | P/E |
|---|---|---|---|
| 2025 | $170.00 | -$5.84 | — |
| 2024 | $123.15 | $8.65 | 14.2 |
| 2023 | $123.00 | $6.10 | 20.2 |
| 2022 | $159.31 | -$3.58 | — |
| 2021 | $127.40 | -$5.52 | — |
| 2020 | $165.05 | $4.22 | 39.1 |
| 2019 | $149.28 | $9.09 | 16.4 |
| 2018 | $123.96 | $7.30 | 17.0 |
| 2017 | $134.65 | $7.96 | 16.9 |
| 2016 | $109.03 | $6.41 | 17.0 |
TickerLandia calculation: closing price on the last trading day of the fiscal year divided by diluted earnings per share from the annual report (positive earnings only). Prices adjusted for splits. Today's P/E is today's price divided by the latest fiscal year's earnings per share, so it compares with the years above.
TickerLandia analysisHow it is calculated
Other metrics
Valuation multiples
- Market cap
- $15.5B
- Enterprise value
- $18.29B
- PEG
- 0.96
- EV/revenue
- 3.88
Profitability and growth
- ROA
- 6.9%
- ROIC
- 8.2%
- Revenue growth (year over year)
- 10.4%
- Earnings growth (year over year)
- -123.7%
Financial health
- Total cash
- $2.86B
- Total debt
- $5.65B
- Current ratio
- 1.82
- Quick ratio
- 1.47
- Altman Z-Score
- 1.96
- Piotroski F-Score
- 6.00
Dividends
- Dividend yield
- 0.0%
- Payout ratio
- 0.0%
Analysts and estimates
- Average price target
- $297.59
- Median price target
- $300.00
- High price target
- $330.00
- Low price target
- $220.00
- Analysts with a price target
- 22
- Consensus
- Strong buy
- Forward EPS
- $26.71
- EPS estimate, current year
- $14.95
Shares and trading
- Beta
- 0.37
- Average volume
- 879.09K
- Shares outstanding
- 64.19M
- Float
- 62.25M
- Institutional ownership
- 106.1%
- Insider ownership
- 3.4%
- Short interest (% of float)
- 9.3%
- Short ratio (days)
- 7.02
